| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LIMD2 |
| Uniprot No | Q9BT23 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-127aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMFQAAGA AQATPSHDAK GGGSSTVQRS KSFSLRAQVK ETCAACQKTV YPMERLVADK LIFHNSCFCC KHCHTKLSLG SYAALHGEFY CKPHFQQLFK SKGNYDEGFG RKQHKELWAH KEVDPGTKTA |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于LIMD2重组蛋白的参考文献摘要(虚构示例，仅供格式参考)：
1. **文献名称**：LIMD2重组蛋白促进肿瘤细胞侵袭的分子机制研究
**作者**：Zhang Y, et al.
**摘要**：本研究通过原核表达系统成功获得高纯度LIMD2重组蛋白，证实其通过激活Integrin β1/FAK信号通路增强乳腺癌细胞的迁移和侵袭能力。
2. **文献名称**：重组LIMD2蛋白在黑色素瘤免疫逃逸中的作用
**作者**：Wang X, Li M.
**摘要**：构建了哺乳动物细胞表达的重组LIMD2蛋白，发现其通过与PD-1受体相互作用抑制T细胞活性，揭示了其在肿瘤免疫微环境中的调控机制。
3. **文献名称**：基于LIMD2重组蛋白的癌症诊断生物标志物开发
**作者**：Chen H, et al.
**摘要**：通过大肠杆菌表达系统制备重组LIMD2蛋白，临床样本检测显示其在肺癌患者血清中显著高表达，提示其作为新型液体活检标志物的潜力。
(注：以上内容为示例模板，实际文献需通过PubMed/Google Scholar检索关键词"LIMD2 recombinant protein"获取。建议使用Web of Science等数据库验证最新研究成果。)
LIMD2 (LIM domain-containing protein 2) is a member of the LIM protein family, characterized by the presence of LIM domains—zinc-binding motifs that mediate protein-protein interactions. It is encoded by the *LIMD2* gene and has garnered attention for its role in cellular adhesion, migration, and cancer progression. Structurally, LIMD2 contains two LIM domains that facilitate interactions with cytoskeletal components and signaling molecules, such as integrins and receptor tyrosine kinases. These interactions position LIMD2 as a regulator of pathways involved in tumor invasion and metastasis.
In cancer biology, LIMD2 is often overexpressed in aggressive malignancies, including melanoma, breast, and lung cancers. Studies suggest it promotes metastatic behavior by enhancing cell motility, suppressing immune surveillance, and modulating the tumor microenvironment. For instance, LIMD2 binds to immune checkpoint ligands like PD-L1. potentially aiding tumor immune evasion. Its expression correlates with poor prognosis, making it a candidate biomarker for disease progression.
Recombinant LIMD2 protein is engineered for research and therapeutic applications. Produced via bacterial or mammalian expression systems, it retains functional domains for in vitro and in vivo studies. Researchers use it to investigate LIMD2’s molecular mechanisms, screen inhibitory compounds, or develop targeted therapies such as monoclonal antibodies. Recent preclinical studies highlight its potential as a therapeutic target, with LIMD2 inhibition shown to reduce tumor growth and metastasis in models.
Overall, LIMD2 recombinant protein serves as a critical tool for unraveling its oncogenic roles and advancing precision oncology strategies.
×
